Get inside Wall Road with StreetInsider Premium. Declare your 1-week free trial here.
Herzliya, Israel and Calgary, Alberta–(Newsfile Corp. – June 14, 2021) – Innocan Pharma Company (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the “Firm” or “Innocan”) is honored to announce it has filed a global patent software for a novel cannabis-based Vaginal Moisturizer and Lubricant Remedy. The composition contains cannabinoids and extra brokers of a phytoestrogen and hyaluronic acid and could also be utilized to alleviate vaginal dryness and vaginal atrophy.
Vaginal moisturizers and lubricants are utilized to assist overcome vaginal dryness and remedy intercourse difficulties. Vaginal dryness is a typical situation confronted by girls of all ages; nevertheless, it’s notably widespread throughout and after the menopause transition. It’s the results of decreased ranges of estrogen, a hormone that retains the liner of the vagina thick, moisturized, and lubricated.
“The vaginal moisturizers and lubricants market is anticipated to develop from USD $2.15 billion in 2021 and attain $3.14 billion by 2026, demonstrating a CAGR of seven.4%,” in line with a report issued on December 2020, by Market Knowledge Forecast.
By increasing its mental property portfolio of cannabis-based merchandise, Innocan Pharma positions itself as a supply of each potential breakthroughs in pores and skin remedy and additional alternatives throughout a broad spectrum of inflammatory indications with presently unmet medical wants.
Iris Bincovich, CEO stated: “Our scientific management has as soon as once more demonstrated the immense potential in incorporating CBD to quite a lot of options, with this software becoming a member of a sequence of 11 patent software filed to this date. Our enlargement right into a multi-billion market comparable to Vaginal Moisturizers and Lubricants is a serious achievement for our firm.”
The Firm, by way of its wholly owned Israeli subsidiary, Innocan Pharma Ltd. (“Innocan Israel”), is a pharmaceutical tech firm that focuses on the event of a number of drug supply platforms combining cannabidiol (“CBD”). Innocan Israel and Ramot at Tel Aviv College are collaborating on a brand new, revolutionary exosome-based know-how that targets each central nervous system (CNS) indications and the COVID-19 Coronavirus utilizing CBD. CBD-loaded exosomes maintain the potential to assist in the restoration of contaminated lung cells. This product, which is anticipated to be administrated by inhalation, might be examined towards quite a lot of lung infections.
Innocan Israel signed a worldwide unique license settlement with Yissum, the business arm of the Hebrew College of Jerusalem to develop a CBD drug supply platform based mostly on a unique-controlled launch liposome to be administrated by injection. Innocan Israel plans, along with Professor Berenholtz, Head of the Laboratory of Membrane and Liposome Analysis of the Hebrew College, to check the liposome platform on a number of potential indications. Innocan Israel can also be engaged on a dermal product that integrates CBD with different pharmaceutical components in addition to the event and sale of CBD-integrated prescription drugs, together with, however not restricted to, topical therapies for aid of psoriasis signs in addition to the remedy of muscle ache and rheumatic ache. The founders and officers of Innocan have commercially profitable observe data within the pharmaceutical and know-how sectors in Israel and globally.
For additional data, please contact:
For Innocan Pharma Company:
Iris Bincovich, CEO
IR: Lytham Companions, LLC
Ben Shamsian CPA | Vice President
Direct: 646-829-9701; Cell: 516-652-9004`Shamsian
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Warning relating to forward-looking data
Sure data set forth on this information launch, together with, with out limitation, data relating to the dimensions of the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking data throughout the which means of relevant securities legal guidelines. By its nature, forward-looking data is topic to quite a few dangers and uncertainties, a few of that are past Innocan’s management. The forward-looking data contained on this information launch relies on sure key expectations and assumptions made by Innocan, together with expectations and assumptions in regards to the anticipated advantages of the merchandise, satisfaction of regulatory necessities in varied jurisdictions and passable completion of requisite manufacturing and distribution preparations.
Ahead-looking data is topic to numerous dangers and uncertainties which might trigger precise outcomes and expertise to vary materially from the anticipated outcomes or expectations expressed on this information launch. The important thing dangers and uncertainties embody however are usually not restricted to: basic international and native (nationwide) financial, market and enterprise situations; governmental and regulatory necessities and actions by governmental authorities; and relationships with suppliers, producers, clients, enterprise companions and opponents. There are additionally dangers which are inherent within the nature of product distribution, together with import / export issues and the failure to acquire any required regulatory and different approvals (or to take action in a well timed method) and availability in every market of product inputs and completed merchandise. The anticipated timeline for entry to markets could change for plenty of causes, together with the shortcoming to safe obligatory regulatory necessities, or the necessity for added time to conclude and/or fulfill the manufacturing and distribution preparations. Because of the foregoing, readers mustn’t place undue reliance on the forward-looking data contained on this information launch in regards to the timing of launch of product distribution. A complete dialogue of different dangers that influence Innocan will also be present in Innocan’s public stories and filings which can be found beneath Innocan’s profile at www.sedar.com.
Readers are cautioned that undue reliance shouldn’t be positioned on forward-looking data as precise outcomes could range materially from the forward-looking data. Innocan doesn’t undertake to replace, appropriate or revise any forward-looking data on account of any new data, future occasions or in any other case, besides as could also be required by relevant legislation.
To view the supply model of this press launch, please go to https://www.newsfilecorp.com/release/87505